NCT03994601
Recruiting
June 21, 2019
April 25, 2022
Brief summary:
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
N/A
Arm | Intervention/treatment |
---|---|
Experimental: Arm A BMS-986288 |
Drug: BMS-986288 Specified dose on specified days |
Experimental: Arm B BMS-986288 in combination with Nivolumab |
Drug: BMS-986288 Specified dose on specified days Drug: Nivolumab Specified dose on specified days |
Inclusion Criteria: Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy Eastern Cooperative Oncology Group Performance Status of 0 or 1 Received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies Exclusion Criteria: Active, known or suspected autoimmune disease Active malignancy requiring concurrent intervention Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the only site of disease, will be excluded Other protocol-defined inclusion/exclusion criteria apply
Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com 855-907-3286 Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.
United States, Colorado
University Of Colorado
Aurora
United States, Maryland
Johns Hopkins University
Baltimore
United States, Missouri
Washington University
Saint Louis
United States, New Jersey
Hackensack University Medical Center
Hackensack
Argentina, Buenos Aires
Local Institution
Ciudad Autónoma De Buenos Aires
Argentina, Cordoba
Local Institution
Río Cuarto
Argentina, Distrito Federal
Local Institution
ABB
Argentina, Distrito Federal
Local Institution
Buenos Aires
Argentina, Distrito Federal
Local Institution - 0012
Caba
Argentina, Distrito Federal
Local Institution
Capital
Argentina
Local Institution
Cordoba
Canada, Ontario
Local Institution - 0006
Toronto
Chile, Metropolitana
Local Institution - 0019
Santiago
Chile, Metropolitana
Local Institution - 0009
Santiago
Chile, Valparaiso
Local Institution
Viña del Mar
France
Local Institution
Bron
France
Local Institution
Marseille
France
Local Institution
Paris
France
Local Institution
Toulon Cedex
Italy
Local Institution
Ancona
Italy
Local Institution
Catanzaro
Italy
Local Institution
Milano
Italy
Local Institution
Milano
Italy
Local Institution
Monza
Spain
Local Institution
Madrid
Spain
Local Institution
Majadahonda
Spain
Local Institution
Valencia
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb